Solving the crisis in psychopharmacological research: Cellular-membrane(s) pharmacology to the rescue?

B. Drukarch*, G. E. Jacobs, M. M.M. Wilhelmus

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

There is an urgent need for the introduction of novel and better (i.e., improved risk-benefit profile) compounds for the treatment of major psychiatric disorders, in particular mood and psychotic disorders. However, despite increased societal awareness and a rising public and professional demand for such agents from patients and physicians, the pharmaceutical industry continues to close down its psychopharmacology research facilities in reaction to the lack of success with the search for new psychotropics. It is high time to stop this untoward trend and explore “new” lines of investigation to solve the current crisis in psychopharmacological research. In line with the prevailing molecular view in drug research in general, also in psychopharmacology mechanistic explanations for drug effects are “traditionally” looked for at the level of molecular targets, like receptors and transporters. Also, more recent approaches, although using so-called systems- and function-based approaches to model the multidimensional characteristics of psychiatric disorders and psychotropic drug action, still emphasize this search strategy for new therapeutic leads by identification of single molecules or molecular pathways. This “psychomolecular gaze” overlooks and disregards the fact that psychotropic agents usually are highly hydrophobic and amphipathic/amphiphilic agents that, in addition to their interaction with membrane-bound proteins in the form of e.g. receptors or transporters, also interact strongly with the lipid component of cellular membranes. Here we suggest to develop a program of systematic, whole-cell level based, investigation into the role of these physical-chemical cellular membrane interactions in the therapeutic action of known psychotherapeutics. This complementary yet conceptually different approach, in our opinion, will complement drug development in psychopharmacology and thereby assist in overcoming the current crisis. In this way the “old” physical theory of drug action, which antedates the current, primary molecular, paradigm may offer “new” options for lead discovery in psychopharmacological research.

Original languageEnglish
Article number110545
JournalBiomedicine and Pharmacotherapy
Volume130
DOIs
Publication statusPublished - Oct 2020

Cite this